Covis Company Profile

✉ Email this page to a colleague

COVIS has eleven approved drugs.

There are five US patents protecting COVIS drugs.

There are one hundred and forty-four patent family members on COVIS drugs in forty-six countries and twenty-seven supplementary protection certificates in fourteen countries.

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Covis	SULAR	nisoldipine	TABLET, EXTENDED RELEASE;ORAL	020356-007	Jan 2, 2008	AB	RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Covis	SULAR	nisoldipine	TABLET, EXTENDED RELEASE;ORAL	020356-005	Jan 2, 2008	AB	RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Covis	LANOXIN PEDIATRIC	digoxin	INJECTABLE;INJECTION	009330-004	Approved Prior to Jan 1, 1982		RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Covis	DUAKLIR PRESSAIR	aclidinium bromide; formoterol fumarate	POWDER, METERED;INHALATION	210595-001	Mar 29, 2019		RX	Yes	Yes	11,000,517	⤷ Sign Up	Y			⤷ Sign Up
Covis	DUAKLIR PRESSAIR	aclidinium bromide; formoterol fumarate	POWDER, METERED;INHALATION	210595-001	Mar 29, 2019		RX	Yes	Yes	8,051,851	⤷ Sign Up	Y			⤷ Sign Up
Covis	TUDORZA PRESSAIR	aclidinium bromide	POWDER, METERED;INHALATION	202450-001	Jul 23, 2012		RX	Yes	Yes	RE46417	⤷ Sign Up	Y	Y		⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Covis	SULAR	nisoldipine	TABLET, EXTENDED RELEASE;ORAL	020356-001	Feb 2, 1995	4,703,038	⤷ Sign Up
Covis	DUAKLIR PRESSAIR	aclidinium bromide; formoterol fumarate	POWDER, METERED;INHALATION	210595-001	Mar 29, 2019	9,056,100	⤷ Sign Up
Covis	SULAR	nisoldipine	TABLET, EXTENDED RELEASE;ORAL	020356-007	Jan 2, 2008	5,422,123	⤷ Sign Up
Covis	SULAR	nisoldipine	TABLET, EXTENDED RELEASE;ORAL	020356-002	Feb 2, 1995	4,892,741	⤷ Sign Up
Covis	ALVESCO	ciclesonide	AEROSOL, METERED;INHALATION	021658-003	Jan 10, 2008	6,036,942	⤷ Sign Up
Covis	ALVESCO	ciclesonide	AEROSOL, METERED;INHALATION	021658-003	Jan 10, 2008	5,695,743	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Nasal Spray	250 mcg	➤ Subscribe	2012-02-13
➤ Subscribe	Extended-release Tablets	25.5 mg and 34 mg	➤ Subscribe	2008-11-28
➤ Subscribe	Extended-release Tablets	8.5 mg and 17 mg	➤ Subscribe	2009-03-02
➤ Subscribe	Injection	30 mg/mL, 17 mL single-use vials	➤ Subscribe	2015-12-04
➤ Subscribe	Extended-release Tablets	20 mg and 30 mg	➤ Subscribe	2007-11-07
➤ Subscribe	Extended-release Tablets	40 mg	➤ Subscribe	2007-06-11

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
Cyprus	1117371	⤷ Sign Up
Montenegro	02286	⤷ Sign Up
Portugal	1200431	⤷ Sign Up
Poland	204024	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2009112274	⤷ Sign Up
Slovenia	2954889	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1169062	2012C/052	Belgium	⤷ Sign Up	PRODUCT NAME: FERUMOXYTOL; AUTHORISATION NUMBER AND DATE: EU/1/12/774/001 20120620
1200431	13C0001	France	⤷ Sign Up	PRODUCT NAME: SEL D'ACLIDINIUM AVEC UN ANION PHARMACEUTIQUEMENT ACCEPTABLE D'UN ACIDE MONO OU POLYVALENT, EN PARTICULIER LE BROMURE D'ACLIDINIUM; REGISTRATION NO/DATE: EU/1/12/778/001-003 20120720
1200431	421	Finland	⤷ Sign Up
1200431	C01200431/01	Switzerland	⤷ Sign Up	PRODUCT NAME: ACLIDINIUM; REGISTRATION NO/DATE: SWISSMEDIC 62590 25.04.2013
1169062	92114	Luxembourg	⤷ Sign Up	PRODUCT NAME: FERUMOXYTOL
1200431	CA 2013 00002	Denmark	⤷ Sign Up
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.